HK1255922A1 - Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases - Google Patents
Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseasesInfo
- Publication number
- HK1255922A1 HK1255922A1 HK18114988.5A HK18114988A HK1255922A1 HK 1255922 A1 HK1255922 A1 HK 1255922A1 HK 18114988 A HK18114988 A HK 18114988A HK 1255922 A1 HK1255922 A1 HK 1255922A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- periostin
- eosinophil
- predictors
- therapeutic agents
- clinical response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250691P | 2015-11-04 | 2015-11-04 | |
| PCT/IB2016/001726 WO2017077391A2 (en) | 2015-11-04 | 2016-11-03 | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1255922A1 true HK1255922A1 (en) | 2019-09-06 |
Family
ID=57737757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18114988.5A HK1255922A1 (en) | 2015-11-04 | 2018-11-23 | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3371225A2 (en) |
| JP (1) | JP2018538249A (en) |
| AU (1) | AU2016349113A1 (en) |
| CA (1) | CA3002761A1 (en) |
| HK (1) | HK1255922A1 (en) |
| WO (1) | WO2017077391A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7444858B2 (en) * | 2018-09-05 | 2024-03-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and compositions for treating asthma and allergic diseases |
| KR102527520B1 (en) * | 2020-09-16 | 2023-05-03 | 순천대학교 산학협력단 | Composition for diagnosis of occupational asthma and method for diagnosis of occupational asthma using the same |
| CA3232203A1 (en) * | 2021-09-22 | 2023-03-30 | James MATTHAEI | Il5ra cell surface markers |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| TW311927B (en) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
| ES2233974T3 (en) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINST THE ALFA CHAIN OF THE 5 HUMAN INTERLEUCINE RECEIVER. |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP1266663A4 (en) | 2000-02-15 | 2003-07-23 | Kyowa Hakko Kogyo Kk | Eosinophil-specific apoptosis inducer |
| WO2004104216A2 (en) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| US20050226867A1 (en) | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
| MX2007005083A (en) | 2004-10-29 | 2007-10-03 | Topigen Pharmaceuticals Inc | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation. |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| WO2008091814A2 (en) * | 2007-01-22 | 2008-07-31 | Wyeth | Assessment of asthma and allergen-dependent gene expression |
| JP2010527356A (en) | 2007-05-14 | 2010-08-12 | メディミューン，エルエルシー | How to reduce eosinophil levels |
| US7833721B2 (en) | 2008-03-14 | 2010-11-16 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
| NZ588853A (en) | 2008-03-31 | 2013-07-26 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
| JP5931442B2 (en) | 2008-08-27 | 2016-06-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Engineered lyophilized formulation of anti-IL-23p19 antibody |
| US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| US20100093552A1 (en) | 2008-10-09 | 2010-04-15 | Asit Panja | Use and identification of biomarkers for gastrointestinal diseases |
| WO2010062663A1 (en) | 2008-11-03 | 2010-06-03 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| JP5736370B2 (en) | 2009-06-25 | 2015-06-17 | ネステク ソシエテ アノニム | Diagnosis of irritable bowel syndrome |
| JP2013511988A (en) | 2009-11-25 | 2013-04-11 | ネステク ソシエテ アノニム | A novel genomic biomarker for the diagnosis of irritable bowel syndrome |
| EA201891433A3 (en) | 2010-01-15 | 2019-02-28 | Кирин-Эмджен, Инк. | COMPOSITION ANTIBODIES AND THERAPEUTIC REGIMES |
| EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
| WO2012094651A2 (en) | 2011-01-06 | 2012-07-12 | The Board Of Trustees Of The University Of Illiois | Scn5a splice variants for use in methods relating to sudden cardiac death and need for implanted cadiac defibrillators |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| WO2012158954A1 (en) | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| ES2716995T3 (en) | 2012-04-03 | 2019-06-18 | Univ Michigan Regents | Biomarkers associated with irritable bowel syndrome and Crohn's disease |
| AU2014306956B2 (en) | 2013-08-12 | 2019-11-21 | Astrazeneca Ab | Methods for reducing exacerbation rates of asthma using benralizumab |
| KR102337601B1 (en) | 2013-08-12 | 2021-12-10 | 아스트라제네카 아베 | Methods for improving asthma symptoms using benralizumab |
| BR112016017192A2 (en) * | 2014-01-27 | 2017-10-10 | Medimmune Llc | dipeptidyl peptidase-4 (dpp4 / cd26) as a peripheral biomarker of il-13 activation in the asthmatic lung |
| WO2015120185A1 (en) | 2014-02-07 | 2015-08-13 | Medimmune, Llc | Novel assay to detect human periostin |
-
2016
- 2016-11-03 WO PCT/IB2016/001726 patent/WO2017077391A2/en active Application Filing
- 2016-11-03 CA CA3002761A patent/CA3002761A1/en not_active Abandoned
- 2016-11-03 EP EP16822517.5A patent/EP3371225A2/en not_active Withdrawn
- 2016-11-03 AU AU2016349113A patent/AU2016349113A1/en not_active Abandoned
- 2016-11-03 JP JP2018521654A patent/JP2018538249A/en active Pending
-
2018
- 2018-11-23 HK HK18114988.5A patent/HK1255922A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017077391A3 (en) | 2017-06-29 |
| JP2018538249A (en) | 2018-12-27 |
| EP3371225A2 (en) | 2018-09-12 |
| AU2016349113A1 (en) | 2018-06-07 |
| CA3002761A1 (en) | 2017-05-11 |
| WO2017077391A2 (en) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1252481A1 (en) | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | |
| EP3349783C0 (en) | Compositions and methods relating to the treatment of diseases | |
| HK1214832A1 (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| SG11201502189UA (en) | Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor | |
| HK1222552A1 (en) | Sobetirome in the treatment of myelination diseases | |
| HUE041553T2 (en) | Methods and compositions for the treatment of monogenic diseases | |
| IL239368A0 (en) | Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases | |
| HK1215868A1 (en) | Bispecific constructs and their use in the treatment of various diseases | |
| EP3010938A4 (en) | Fcrn-specific human antibody and composition for treatment of autoimmune diseases | |
| EP2819687A4 (en) | Compositions and methods for treatment of peripheral vascular disease | |
| TWI561521B (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| PL2683826T3 (en) | Use of aptamers in therapy and/or diagnosis of autoimmune diseases | |
| PL3466425T3 (en) | Use of glutarimide derivatives in the treatment of eosinophilic diseases | |
| GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
| HK1255922A1 (en) | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases | |
| PL2892556T3 (en) | Compositions and methods relating to the treatment of diseases | |
| HK1212225A1 (en) | Therapeutic formulation and methods of treatment | |
| EP2709632A4 (en) | Compositions and methods for the treatment of skin diseases | |
| ZA201901090B (en) | Therapeutic combinations to treat red blood cell disorders | |
| EP2934543A4 (en) | Stimulation and enhancement of regeneration of tissues | |
| ZA201603098B (en) | Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases | |
| HK1216721A1 (en) | Uses and methods for the treatment of liver diseases or conditions | |
| IL242694B (en) | Human monocyte sub-population for treatment of eye diseases and disorders | |
| EP2838509A4 (en) | Formulations and methods for treatment of inflammatory skin diseases | |
| HK1218882A1 (en) | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases |